JP2018186833A5 - - Google Patents

Download PDF

Info

Publication number
JP2018186833A5
JP2018186833A5 JP2018149864A JP2018149864A JP2018186833A5 JP 2018186833 A5 JP2018186833 A5 JP 2018186833A5 JP 2018149864 A JP2018149864 A JP 2018149864A JP 2018149864 A JP2018149864 A JP 2018149864A JP 2018186833 A5 JP2018186833 A5 JP 2018186833A5
Authority
JP
Japan
Prior art keywords
seq
protein consisting
composition
amount
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018149864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018186833A (ja
Filing date
Publication date
Priority claimed from US13/663,527 external-priority patent/US10028998B2/en
Application filed filed Critical
Publication of JP2018186833A publication Critical patent/JP2018186833A/ja
Publication of JP2018186833A5 publication Critical patent/JP2018186833A5/ja
Pending legal-status Critical Current

Links

JP2018149864A 2012-10-30 2018-08-09 Fcγ受容体IIB変異体 Pending JP2018186833A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US13/663,527 2012-10-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015538506A Division JP6423351B2 (ja) 2012-10-30 2013-10-30 Fcγ受容体IIB変異体

Publications (2)

Publication Number Publication Date
JP2018186833A JP2018186833A (ja) 2018-11-29
JP2018186833A5 true JP2018186833A5 (cg-RX-API-DMAC7.html) 2019-01-17

Family

ID=49679480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015538506A Active JP6423351B2 (ja) 2012-10-30 2013-10-30 Fcγ受容体IIB変異体
JP2018149864A Pending JP2018186833A (ja) 2012-10-30 2018-08-09 Fcγ受容体IIB変異体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015538506A Active JP6423351B2 (ja) 2012-10-30 2013-10-30 Fcγ受容体IIB変異体

Country Status (27)

Country Link
US (1) US10028998B2 (cg-RX-API-DMAC7.html)
EP (1) EP2914624B1 (cg-RX-API-DMAC7.html)
JP (2) JP6423351B2 (cg-RX-API-DMAC7.html)
KR (1) KR102170674B1 (cg-RX-API-DMAC7.html)
CN (1) CN104918955B (cg-RX-API-DMAC7.html)
AU (1) AU2013340831B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008815A2 (cg-RX-API-DMAC7.html)
CA (1) CA2887164C (cg-RX-API-DMAC7.html)
CL (1) CL2015001127A1 (cg-RX-API-DMAC7.html)
DK (1) DK2914624T3 (cg-RX-API-DMAC7.html)
EA (1) EA033437B9 (cg-RX-API-DMAC7.html)
ES (1) ES2628049T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170894T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032786T2 (cg-RX-API-DMAC7.html)
IL (1) IL238528A (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03206A (cg-RX-API-DMAC7.html)
LT (1) LT2914624T (cg-RX-API-DMAC7.html)
MX (1) MX359802B (cg-RX-API-DMAC7.html)
MY (1) MY173686A (cg-RX-API-DMAC7.html)
NZ (1) NZ706884A (cg-RX-API-DMAC7.html)
PH (1) PH12015500771B1 (cg-RX-API-DMAC7.html)
PL (1) PL2914624T3 (cg-RX-API-DMAC7.html)
PT (1) PT2914624T (cg-RX-API-DMAC7.html)
RS (1) RS56075B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201502749VA (cg-RX-API-DMAC7.html)
SI (1) SI2914624T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014068012A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
KR102138219B1 (ko) 2013-10-16 2020-07-28 수프레몰 게엠베하 자가면역 수포성 질환의 치료를 위한 가용성 Fc 감마 수용체
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えFcγRIIb
EP3810337A1 (de) * 2018-06-25 2021-04-28 BASF Coatings GmbH Verfahren zur herstellung einer optimierten beschichtung und mittels dieses verfahrens erhältliche beschichtung
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
AU2023367781A1 (en) 2022-10-25 2025-06-05 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
EP0833907A1 (en) 1995-06-23 1998-04-08 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1709073B1 (en) 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)
PL1960427T3 (pl) 2005-12-13 2011-07-29 Suppremol Gmbh Multimeryczne polipeptydy receptora Fc
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein

Similar Documents

Publication Publication Date Title
JP2018186833A5 (cg-RX-API-DMAC7.html)
JP2018100276A5 (cg-RX-API-DMAC7.html)
JP2021502979A5 (cg-RX-API-DMAC7.html)
JP2018012698A5 (cg-RX-API-DMAC7.html)
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG11202007074PA (en) Anti-claudin 18.2 antibodies and uses thereof
JP2019142968A5 (cg-RX-API-DMAC7.html)
JP2021503478A5 (cg-RX-API-DMAC7.html)
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
CN109843893A (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
JP2017048194A5 (cg-RX-API-DMAC7.html)
MY209489A (en) Antibody against human il-4ra and use thereof
JPWO2020148954A5 (cg-RX-API-DMAC7.html)
JP2018064407A5 (cg-RX-API-DMAC7.html)
JP2017140920A5 (cg-RX-API-DMAC7.html)
JP2020532288A5 (cg-RX-API-DMAC7.html)
MX2023014145A (es) Oligonucleotidos modificados y metodos de uso.
JP2017501211A5 (cg-RX-API-DMAC7.html)
JP2018127649A5 (cg-RX-API-DMAC7.html)
LT3979827T (lt) Maistinė kompozicija, apimanti 2‘-fukozillaktozę ir 3‘-galaktozillaktozę
JP2007510403A5 (cg-RX-API-DMAC7.html)
EP3789382A4 (en) PROCESS FOR THE PRODUCTION OF 4,5-DIHYDROISOXAZOLE 5,5-DISUBSTITUTED
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
JP2019512693A5 (cg-RX-API-DMAC7.html)
JP2020531778A5 (cg-RX-API-DMAC7.html)